Business Standard

AstraZeneca Pharma hits fresh record high of Rs 4,489; stock surges 15%

The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period.

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Premium

AstraZeneca Plc, the company's parent firm, is expected to release initial data on whether a vaccine can stop people from getting the virus on September 15.

SI Reporter Mumbai
Continuing their northward movement, shares of Astrazeneca Pharma India hit a fresh record high of Rs 4,489, up 15 per cent on the BSE on Monday, in an otherwise range-bound market, amid expectation that the company’s candidate, AZD1222, could be viewed as a frontrunner in a global race to deliver an effective vaccine to combat the Covid-19 virus.

At 03:05 pm, the stock was trading 13 per cent higher at Rs 4,411 on the BSE. In comparison, the S&P BSE Sensex was trading 0.36 per cent lower at 38,218 points. The stock of the pharmaceutical company was trading higher

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in